Member Info for OAPK20

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April, 2020
Commission File Number: 001-38452

Mereo BioPharma

On March 4, 2020, the U.S. Securities and Exchange Commission (the “SEC”) issued an order under Section 36 (Release No. 34-88318) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), granting exemptions from specified provisions of the Exchange Act and certain rules thereunder. On March 25, 2020, the order was modified and superseded by a new SEC order (Release No. 34-88465), which provides conditional relief to public companies that are unable to timely comply with their filing obligations as a result of the novel coronavirus (“COVID-19”) outbreak (the “SEC Order”). The SEC Order provides that a registrant subject to the reporting requirements of Exchange Act Section 13(a) or 15(d), and any person required to make any filings with respect to such registrant, is exempt from any requirement to file or furnish materials with the Commission under Exchange Act Sections 13(a), 13(f), 13(g), 14(a), 14(c), 14(f), 15(d) and Regulations 13A, Regulation 13D-G (except for those provisions mandating the filing of Schedule 13D or amendments to Schedule 13D), 14A, 14C and 15D, and Exchange Act Rules 13f-1, and 14f-1, as applicable, if certain conditions are satisfied.
Mereo BioPharma Group plc (the “Company”) will be relying on the SEC Order to delay the filing of its Annual Report on Form 20-F for the year ended December 31, 2019 (the “Report”) due to circumstances related to COVID-19, which include disruptions to operations in terms of travel and limited access to the Company’s facilities resulting in an impact to staff’s ability to carry out some of their usual work. Potential investors and business partners also face increased challenges to complete the processes necessary to move ahead with an investment or partnership decision because of COVID-19’s impact on the business of potential investors or partners and their ability to complete the diligence process in a COVID-19 environment alongside a broader dynamic of highly volatile equity markets which are also adversely affecting this process. Notwithstanding the foregoing, the Company plans to file the Report no later than June 15, 2020 (which is 45 days from the Report’s original filing deadline of April 30, 2020).
In light of the current COVID-19 pandemic, the Company will be including the following Risk Factor in its Report:
The COVID-19 pandemic or any other similar pandemic may materially impact our business including our ability to obtain further financial investment and planned clinical developments.
The outbreak of COVID-19 has developed into a global pandemic, spreading to most regions of the world including the United States and the United Kingdom and to locations where we have facilities or ongoing clinica

Truff. It’s available on MREO listing. Here is The full Form 6 K

Blue. I have never met you. I don’t care for status never have never will. I m sure though you are probably a very nice person face to face, rather than behind a key board. Good luck with your investments, i have done extremely well, by my standards. And that is all that matters to me. I have no income worries and a 6 figure war chest to call on, on top of my current holdings. I know that may not be in your league. Every BB has a self appointed expert and it appears the LSE SLE bb has you.
I bow to your superior intellect. For every hundred or so BB posts you find at least one gem of information. When you throw bait you eventually get a bite. First throw here.

The sort of reply expected from the self appointed resident BB font of all knowledge poster.

Worse than the Lloyd’s bb board.

Dual listing so best to check releases both sides of the pond.

28th April - MREO.

Mereo BioPharma Group plc Intends to Rely on SEC Relief and Delay Filing of its 2019 Annual Report on Form 20-F
On March 4, 2020, the U.S. Securities and Exchange Commission (the “SEC”) issued an order under Section 36 (Release No. 34-88318) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), granting exemptions from specified provisions of the Exchange Act and certain rules thereunder. On March 25, 2020, the order was modified and superseded by a new SEC order (Release No. 34-88465), which provides conditional relief to public companies that are unable to timely comply with their filing obligations as a result of the novel coronavirus (“COVID-19”) outbreak (the “SEC Order”). The SEC Order provides that a registrant subject to the reporting requirements of Exchange Act Section 13(a) or 15(d), and any person required to make any filings with respect to such registrant, is exempt from any requirement to file or furnish materials with the Commission under Exchange Act Sections 13(a), 13(f), 13(g), 14(a), 14(c), 14(f), 15(d) and Regulations 13A, Regulation 13D-G (except for those provisions mandating the filing of Schedule 13D or amendments to Schedule 13D), 14A, 14C and 15D, and Exchange Act Rules 13f-1, and 14f-1, as applicable, if certain conditions are satisfied.
Mereo BioPharma Group plc (the “Company”) will be relying on the SEC Order to delay the filing of its Annual Report on Form 20-F for the year ended December 31, 2019 (the “Report”) due to circumstances related to COVID-19, which include disruptions to operations in terms of travel and limited access to the Company’s facilities resulting in an impact to staff’s ability to carry out some of their usual work. Potential investors and business partners also face increased challenges to complete the processes necessary to move ahead with an investment or partnership decision because of COVID-19’s impact on the business of potential investors or partners and their ability to complete the diligence process in a COVID-19 environment alongside a broader dynamic of highly volatile equity markets which are also adversely affecting this process. Notwithstanding the foregoing, the Company plans to file the Report no later than June 15, 2020 (which is 45 days from the Report’s original filing deadline of April 30, 2020).

28th April - MREO.

Mereo BioPharma Group plc Intends to Rely on SEC Relief and Delay Filing of its 2019 Annual Report on Form 20-F
On March 4, 2020, the U.S. Securities and Exchange Commission (the “SEC”) issued an order under Section 36 (Release No. 34-88318) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), granting exemptions from specified provisions of the Exchange Act and certain rules thereunder. On March 25, 2020, the order was modified and superseded by a new SEC order (Release No. 34-88465), which provides conditional relief to public companies that are unable to timely comply with their filing obligations as a result of the novel coronavirus (“COVID-19”) outbreak (the “SEC Order”). The SEC Order provides that a registrant subject to the reporting requirements of Exchange Act Section 13(a) or 15(d), and any person required to make any filings with respect to such registrant, is exempt from any requirement to file or furnish materials with the Commission under Exchange Act Sections 13(a), 13(f), 13(g), 14(a), 14(c), 14(f), 15(d) and Regulations 13A, Regulation 13D-G (except for those provisions mandating the filing of Schedule 13D or amendments to Schedule 13D), 14A, 14C and 15D, and Exchange Act Rules 13f-1, and 14f-1, as applicable, if certain conditions are satisfied.
Mereo BioPharma Group plc (the “Company”) will be relying on the SEC Order to delay the filing of its Annual Report on Form 20-F for the year ended December 31, 2019 (the “Report”) due to circumstances related to COVID-19, which include disruptions to operations in terms of travel and limited access to the Company’s facilities resulting in an impact to staff’s ability to carry out some of their usual work. Potential investors and business partners also face increased challenges to complete the processes necessary to move ahead with an investment or partnership decision because of COVID-19’s impact on the business of potential investors or partners and their ability to complete the diligence process in a COVID-19 environment alongside a broader dynamic of highly volatile equity markets which are also adversely affecting this process. Notwithstanding the foregoing, the Company plans to file the Report no later than June 15, 2020 (which is 45 days from the Report’s original filing deadline of April 30, 2020).

Why the delay in Final results?

Is there a difference in Post Dividend and post ex date? Apart from the date? Asking “ cough “ for a friend....

How do you arrive at 21.5. Is it just as simple as taking 6p off the sp? What valuation is being placed on the company to get to 21.5 ?

Evening. Is there a consensus on this board re potential sp post Dividend. Would 27 - 32 be a fair estimate before SLE declare the expected dividends from its indirect shareholding in Eroton, on top of balance repayments of Loan notes and accrued interest.

Company plans to file the Report no later than June 15, 2020 (which is 45 days from the Report’s original filing deadline of April 30, 2020).

Standby your beds. 232000 delayed trade at 24.8448 which just popped up.

Have the two Major shareholders finished selling yet ? Sorry reducing I know the "s" word freaks people out. How long until the overhang clears ? News due.

"Them"

Cant be many companies with a product looking to integrate with technology and AI in Pharma. Any insights as the time scale with China deployment.

Are Craig Auringer and Ron Valk still selling into the rise. Sorry reducing I appreciate the " s " really freaks out some. How long until the overhang clears ?

Don't they use the spread to hide buys and sells to their own advantage?

Employees exercising their share options before news. In the money with their 60,000 shares.

Good luck